How Bristol Myers Squibb Is Accelerating Drug Development With AI - Ep. 264

What It Covers

Bristol Myers Squibb's Chief Digital Officer Greg Myers explains how AI accelerates drug discovery and development, reducing clinical trial timelines by three years and enabling predictive molecule invention across their pharmaceutical pipeline.

Key Questions Answered

• •Predictive Molecule Invention: Bristol Myers Squibb now requires predictive AI model validation before running 100% of small molecule and 50% of large molecule wet lab experiments, resulting in measurably higher success rates in research outcomes.
• •Clinical Trial Acceleration: AI-powered tools generate 80% of informed consent forms automatically and assist with 300+ required clinical trial documents, contributing to a three-year reduction in the typical ten-year drug development timeline.
• •Early Disease Detection: AI analysis of standard twelve-lead ECG readings can detect hypertrophic cardiomyopathy signatures invisible to human physicians, enabling diagnosis years earlier and preventing sudden cardiac death in young athletes and undiagnosed patients.
• •Internal AI Deployment Strategy: Bristol Myers Squibb deployed internal chatbots three months after ChatGPT 3.5 launched, now providing employees free access to multiple frontier models including GPT-4, Claude, and Gemini plus 2,500 Microsoft Copilot licenses.